$VERU

BARNETTE K GARY purchased $5K of VERU

BARNETTE K GARY (Chief Scientific Officer) purchased 1,800 shares of VERU INC. (VERU) at $2.69 on 2026-08-13.

Original reporting
SEC EDGAR · BARNETTE K GARY
Published Aug 17, 2026, 8:26 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 17, 2026, 8:44 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$VERU
Neutral
low confidence
Mentioned
$VERU
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$VERUNeutralLow
01

Why it matters

The only new fact is the insider’s open-market purchase size, price, and post-transaction holdings; it does not include guidance, trial results, or corporate actions.

02

Market read

Traders may note insider buying as a minor sentiment input, but there is no fundamental update to reprice the stock materially.

03

What to watch

The text notes no pre-arranged 10b5-1 plan, but it still does not reveal intent, timing constraints, or whether the purchase is part of a broader pattern.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-17, transaction dated 2026-08-13

Background

The article is an SEC Form 4 insider transaction disclosure for VERU.

Company-level read

Ticker impact

$VERUNeutralLow confidence
Context

SEC Form 4 shows Chief Scientific Officer Barnette K. Gary bought 1,800 VERU shares at $2.6899 on 2026-08-13.

Expected impact

Limited near-term impact; any effect is likely sentiment-driven and small versus broader company fundamentals.

Evidence & confidence

The filing is a routine insider transaction with no new operational, financial, or regulatory information disclosed in the text.

Market effects

No sector-level implications are provided beyond a single insider trade.

None indicated.

None indicated.

Counterpoint

Insider buys can be discretionary, tax-related, or part of routine compensation activity, so the signal may be weak.

Key entities

  • VERU

    Issuer of the Form 4 insider transaction disclosed in the article.

  • BARNETTE K GARY

    Chief Scientific Officer at VERU who purchased shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$VERUMed

VERU INC. (VERU): Results of Operations and Financial Condition

VERU INC. (VERU) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Investor and Media Contact: Samuel Fisch Executive Director, Investor Relations and Corporate Communications Email: veruinvestor@verupharma.com Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress — Phase 2b PLATEAU cl